During its performance briefing, Lepu Medical disclosed that its implantable deep brain neurostimulator (DBS) is on the verge of receiving market approval. This product is projected to start generating revenue for the company in the coming year. In addition, plans are in place to submit the implantable cardiac contractility modulator (CCM) for regulatory approval during the first and second quarters of next year. The neuromodulation business division is set to emerge as a fresh catalyst for the company's performance expansion. In light of the centralized procurement policy, Lepu Medical is channeling its efforts into the development of implantable and interventional medical devices. These devices boast higher technical hurdles and stronger market competitiveness, which is a strategic move to counterbalance the potential impact of centralized procurement on its business operations.